Kyverna Therapeutics, Inc.
NASDAQ:KYTXBiotechnology
-$0.12 today
- Market cap
- $283.23M
- Beta
- 1.96
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$2.59
Volume 1.05M
Average 0.94M
KYTX Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Kyverna Therapeutics, Inc.NASDAQ: KYTX
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments rises 9.9% from a year ago
Short-term investments stood at $204.25M at the end of Q1 FY2026, up 9.9% from a year earlier and up 31.6% from the prior quarter. Over 3 fiscal years it compounded at +125.2% a year.
Context
- Short-term investments amounted to 79.5% of total assets at the end of Q1 FY2026, up 8.2 pp from a year earlier.
- Short-term investments increased in 2 of the last 3 fiscal years.
What to watch
Whether short-term investments keeps rising in the next quarterly balance sheet after a +9.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 155.16M USD
- Year-over-year change
- -18.1%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 155.16M | -18.1% |
| FY2024 | 2024-12-31 | 189.36M | +727.0% |
| FY2023 | 2023-12-31 | 22.9M | +68.5% |
| FY2022 | 2022-12-31 | 13.59M | — |
| FY2021 | 2021-12-31 | 0 | — |
Short-term Investments vs competitors
How KYTX compares with its peers on the latest reported figures
- KYTX's Mar 2026 short-term investments of $204.25M is the 3rd highest of the 11 companies compared; the peer median is $113.84M.
- Its year-over-year change of +9.9% is the 3rd highest of 9, against a peer median of -9.9%.
- Short-term investments amounts to 79.5% of total assets for KYTX, versus a peer median of 49.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $236.58M | -0.4% | -24.2% | 59.7% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $226.17M | +34.4% | +65.0% | 86.5% |
| Mar 2026 | $204.25M | +9.9% | +125.2% | 79.5% | |
| Mar 2026 | $176.69M | -42.3% | — | 66.2% | |
| Mar 2026 | $173.19M | +49.3% | -1.6% | 53.1% | |
| Mar 2026 | $163.25M | -9.7% | -28.7% | 46.6% | |
| Mar 2026 | $64.42M | -10.1% | +65.4% | 56.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Mar 2026 | $0 | — | +26.6% | 0.0% | |
LXEOLexeo Therapeutics, Inc. Common Stock | Mar 2026 | $0 | -100.0% | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding KYTX) | $113.84M | -9.9% | +12.5% | 49.8% | |
Competitors are the stored peer set for KYTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 76.07M | 37.74M | 34.65M | 96.62M | 124.09M |
| Short-term Investments | 0 | 13.59M | 22.9M | 189.36M | 155.16M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.02M | 1.93M | 3.12M | 4.62M | 3.7M |
| Total Current Assets | 77.09M | 53.25M | 60.66M | 290.6M | 282.95M |
| Property, Plant & Equipment (Net) | 7.81M | 12.44M | 10.61M | 10.66M | 5.42M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 593K | 1.23M | 3.92M | 5.26M | 5.45M |
| Total Non-current Assets | 8.4M | 13.67M | 14.53M | 15.92M | 10.87M |
| Total Assets | 85.49M | 66.92M | 75.2M | 304.65M | 293.83M |
| Account Payables | 773K | 1.45M | 4.36M | 4.62M | 5.31M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 6M | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.72M | 565K | 9.77M | 4.88M | 9.99M |
| Total Current Liabilities | 15.93M | 11.95M | 19.86M | 33.76M | 36.49M |
| Long-term Debt | 0 | 0 | 0 | 0 | 24.74M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 1.03M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 110.05M | 6K | 0 | 0 | 0 |
| Total Non-current Liabilities | 115.81M | 8.29M | 6.16M | 4.3M | 25.06M |
| Total Liabilities | 131.74M | 20.25M | 26.02M | 38.06M | 61.55M |
| Common Stock | 0 | 0 | 0 | 0 | 1K |
| Retained Earnings | (46.78M) | (75.68M) | (136.04M) | (263.52M) | (424.83M) |
| Accumulated OCI | 0 | (26K) | 4K | 105K | 97K |
| Other Stockholders Equity | 0 | (0) | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (46.25M) | 46.68M | 49.18M | 266.59M | 232.28M |
| Total Debt | 5.56M | 10.56M | 9.08M | 8.24M | 29.03M |
| Net Debt | (70.51M) | (27.17M) | (25.57M) | (88.38M) | (95.06M) |
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
Intrinsic Alpha fair value
Locked
Current Price
$4.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.